HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Monograph Reform Momentum Carries Potential Exclusivity Snag

This article was originally published in The Rose Sheet

Executive Summary

Support was unanimous during House Health Subcommittee markup for draft legislation on streamlining FDA's monograph system by eliminating public rulemakings from the process and allowing the agency to make decisions with administrative orders. Two-year exclusivity for some products didn't go over so well.

Advertisement

Related Content

OTC Monograph Legislation Clears Another Hurdle Despite Exclusivity Concerns
Rep. Pallone's Push For Cosmetics Reform Falls Flat During OTC Monograph Bill Markup
Cosmetic Regulation Update's Link With OTC Drug User Fees Clear At Hearing
Waiting For Congress: Reforming, Paying For FDA OTC Monograph Program
OTC Monograph User Fees Up To $34M Floated In Senate Discussion Draft

Topics

Advertisement
UsernamePublicRestriction

Register

RS121419

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel